Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Exelixis, Inc
Femme Max 99 ans
Exelixis, Inc
MAJ Il y a 4 ans
A Phase 2 Study of XL147 in Subjects with Advanced or Recurrent Endometrial Carcinoma
The primary objectives of this study are: • To estimate the efficacy endpoints of: 1) ORR (confirmed complete response [CR] or confirmed PR), and 2) rate of 6-month PFS (PFS6) of XL147 in relation to ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Homme Max 99 ans
Exelixis, Inc
MAJ Il y a 4 ans
A Study to Determine the Safety and Efficacy of Cabozantinib (XL184) in Patients with Metastatic Castration-resistant Prostate Cancer who have Received Prior Docetaxel and Prior Abiraterone or MDV3100
The objective of this study is to evaluate the effect of cabozantinib compared to prednisone on overall survival in men with previously treated metastatic castration-resistant prostate cancer with bon...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Exelixis, Inc
MAJ Il y a 4 ans
An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 versus Placebo in Subjects with Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer
To evaluate progression free survival (PFS) with XL184 treatment as compared with placebo in subjects with unresectable, locally advanced or metastatic medullary thyroid carcinoma (MTC).
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Exelixis, Inc
MAJ Il y a 4 ans
A study of cabozantinib vs. placebo in subjects with a form of liver cancer who have previously received sorafenib
The objective of this study is to evaluate the effect of cabozantinib compared with placebo on overall survival in subjects with advanced HCC previously treated with sorafenib.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme Max 99 ans
Exelixis, Inc
MAJ Il y a 4 ans
A Phase 1/2 Study of XL147 Administered in Combination with Trastuzumab or Paclitaxel and Trastuzumab in Subjects with Metastatic Breast Cancer who have Progressed on a Previous Trastuzumab- Based Regimen
The primary objectives are: • To evaluate the safety and tolerability of XL147 in combination with trastuzumab and in combination with trastuzumab and paclitaxel. • To determine the maximum tolerated ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations